Steinbeis, Fridolin
Thibeault, Charlotte
Steinbrecher, Sarah
Ahlgrimm, Yvonne
Haack, Ira an
August, Dietrich
Balzuweit, Beate
Bellinghausen, Carla
Berger, Sarah
Chaplinskaya-Sobol, Irina
Cornely, Oliver
Doeblin, Patrick
Endres, Matthias
Fink, Claudia
Finke, Carsten
Frank, Sandra
Hanß, Sabine
Hartung, Tim
Hellmuth, Johannes Christian
Herold, Susanne
Heuschmann, Peter
Heyckendorf, Jan
Heyder, Ralf
Hippenstiel, Stefan
Hoffmann, Wolfgang
Kelle, Sebastian Ulrich
Knape, Philipp
Koehler, Philipp
Kretzler, Lucie
Leistner, David Manuel
Lienau, Jasmin
Lorbeer, Roberto
Lorenz-Depiereux, Bettina
Lüttke, Constanze Dorothea
Mai, Knut
Merle, Uta
Meyer-Arndt, Lil Antonia
Miljukov, Olga
Muenchhoff, Maximilian
Müller-Plathe, Moritz
Neuhann, Julia
Neuhauser, Hannelore
Nieters, Alexandra
Otte, Christian
Pape, Daniel
Pinto, Rafaela Maria
Pley, Christina
Pudszuhn, Annett
Reuken, Philipp
Rieg, Siegberg
Ritter, Petra
Rohde, Gernot
Rönnefarth, Maria
Ruzicka, Michael
Schaller, Jens
Schmidt, Anne
Schmidt, Sein
Schwachmeyer, Verena
Schwanitz, Georg
Seeger, Werner
Stahl, Dana
Stobäus, Nicole
Stubbe, Hans Christian
Suttorp, Norbert
Temmesfeld, Bettina
Thun, Sylvia
Triller, Paul
Trinkmann, Frederik
Vadasz, Istvan
Valentin, Heike
Vehreschild, Maria
von Kalle, Christof
von Lilienfeld-Toal, Marie
Weber, Joachim
Welte, Tobias
Wildberg, Christian
Wizimirski, Robert
Zvork, Saskia
Sander, Leif Erik
Vehreschild, Janne
Zoller, Thomas
Kurth, Florian
Witzenrath, Martin
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 1 May 2023
Accepted: 29 May 2023
First Online: 11 July 2023
Declarations
:
: BC received research funding from Gilead Sciences outside the submitted work. OAC reports grants or contracts from Amplyx, Basilea, BMBF, Cidara, DZIF, EU-DG RTD (101037867), F2G, Gilead, Matinas, MedPace, MSD, Mundipharma, Octapharma, Pfizer, Scynexis; consulting fees from Abbvie, Amplyx, Biocon, Biosys, Cidara, Da Volterra, Gilead, IQVIA, Janssen, Matinas, MedPace, Menarini, Molecular Partners, MSG-ERC, Noxxon, Octapharma, Pardes, Pfizer, PSI, Scynexis, Seres; honoraria for lectures from Abbott, Abbvie, Al-Jazeera Pharmaceuticals, Astellas, Gilead, Grupo Biotoscana/United Medical/Knight, Hikma, MedScape, MedUpdate, Merck/MSD, Mylan, Noscendo, Pfizer, Shionogi; payment for expert testimony from Cidara; participation on a Data Safety Monitoring Board or Advisory Board from Actelion, Allecra, Cidara, Entasis, IQVIA, Janssen, MedPace, Paratek, PSI, Pulmocide, Shionogi, The Prime Meridian Group; A patent at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); stocks from CoRe Consulting, EasyRadiology; other interests from DGHO, DGI, ECMM, ISHAM, MSG-ERC, Wiley. ME received funding from DFG under Germany’s Excellence Strategy-EXC-2049-390688087, Collaborative Research Center ReTune TRR 295-424778381, BMBF, DZNE, DZHK, EU, Corona Foundation, and Fondation Leducq; ME reports grants from Bayer and fees paid to the Charité from Abbot, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, GSK, Sanofi, Covidien, Novartis, Pfizer, all outside the submitted work. HS received advisor honoraria from Janssen, AstraZeneca, Sanofi, Atriva. PUH reports grants from German Ministry of Research and Education, European Union, Charité-Universitätsmedizin Berlin, Berlin Chamber of Physicians, German Parkinson Society, University Hospital Würzburg, Robert Koch Institute, German Heart Foundation, Federal Joint Committee (G-BA) within the Innovationfond, German Research Foundation, Bavarian State, German Cancer Aid, Charité-Universitätsmedizin Berlin (within Mondafis; supported by an unrestricted research grant to the Charité from Bayer), University Göttingen (within FIND-AF randomized; supported by an unrestricted research grant to the University Göttingen from Boehringer-Ingelheim), University Hospital Heidelberg (within RASUNOA-prime; supported by an unrestricted research grant to the University Hospital Heidelberg from Bayer, BMS, Boehringer-Ingelheim, Daiichi Sankyo), outside the submitted work. PK reports grants or contracts from German Federal Ministry of Research and Education (BMBF) B-FAST (Bundesweites Forschungsnetz Angewandte Surveillance und Testung) and NAPKON (Nationales Pandemie Kohorten Netz, German National Pandemic Cohort Network) of the Network University Medicine (NUM) and the State of North Rhine-Westphalia; Consulting fees Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited, Noxxon N.V. and Pfizer Pharma; honoraria for lectures from Akademie für Infektionsmedizin e.V., Ambu GmbH, Astellas Pharma, BioRad Laboratories Inc., Datamed GmbH, European Confederation of Medical Mycology, Gilead Sciences, GPR Academy Ruesselsheim, HELIOS Kliniken GmbH, Lahn-Dill-Kliniken GmbH, medupdate GmbH, MedMedia, MSD Sharp & Dohme GmbH, Pfizer Pharma GmbH, Scilink Comunicación Científica SC and University Hospital and LMU Munich; Participation on an Advisory Board from Ambu GmbH, Gilead Sciences, Mundipharma Resarch Limited and Pfizer Pharma; a pending patent currently reviewed at the German Patent and Trade Mark Office (DE 10 2021 113 007.7); other non-financial interests from Elsevier, Wiley and Taylor & Francis online outside the submitted work. OC received honoraria for lectures and/or scientific advice from Fortbildungskolleg, Janssen, Lundbeck, Limes Klinikgruppe, Neuraxpharm, and Peak Profiling Research Funding from the German Research Foundation (OT 209/7-3; 14-1, 19-1, EXC 2049), the European Commission (IMI2 859366), the German Federal Ministry of Education and Research (KS2017-067), and the Berlin Institute of Health (B3010350). DP received support for attending ECCMID 2021 from Advanz Pharma Germany. PR reports lecture fees from Pfizer, BMS, CSL Behring and Gilead and served as an Advisory Board Member for Pfizer and Gilead. SR reports honoraria for lectures from Med Update GmbH, Pfizer, and Falk Foundation. GR reports personal fees from Astra Zeneca, Atriva, Boehringer Ingelheim, GSK, Insmed, MSD, Sanofi, Novartis and Pfizer for consultancy during advisory board meetings. GR reports personal fees from Astra Zeneca, Berlin Chemie, BMS, Boehringer Ingelheim, Chiesi, Essex Pharma, Grifols, GSK, Insmed, MSD, Roche, Sanofi, Solvay, Takeda, Novartis, Pfizer and Vertex for lectures. WS received consulting fees from United Therapeutics, Tiakis Biotech AG, Liquidia, Pieris Pharmaceuticals, Abivax, Pfizer. FT received travel support from Actelion, Berlin Chemie, Boehringer Ingelheim, Chiesi, Novartis, Mundipharma and TEVA as well as speaker or consultation fees from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Fisher & Paykel, GlaxoSmithKline, Roche, Novartis, OM Pharma and Sanofi-Aventis. IV received research grants from the German Research Foundation (DFG): DFG/KFO309, project ID: 284237345; P5 and EXC 2026, project ID: 390649896, from the Federal Ministry of Education and Research: DZL/ALI 1.5 und 3.4 and form the von Behring Röntgen Foundation: project 66-LV07. JJV has personal fees from Merck/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), University Hospital Freiburg/Congress and Communication, Academy for Infectious Medicine, University Manchester, German Society for Infectious Diseases (DGI), Ärztekammer Nordrhein, University Hospital Aachen, Back Bay Strategies, German Society for Internal Medicine (DGIM), Shionogi, Molecular Health, Netzwerk Universitätsmedizin, Janssen, NordForsk, Biontech, APOGEPHA and grants from Merck/MSD, Gilead, Pfizer, Astellas Pharma, Basilea, German Centre for Infection Research (DZIF), German Federal Ministry of Education and Research (BMBF), Deutsches Zetrum für Luft- und Raumfahrt (DLR), University of Bristol, Rigshospitalet Copenhagen. MJGTV has received research grants from 3M, Astellas Pharma, Biontech, DaVolterra, Evonik, Gilead Sciences, Glycom, Immunic, MaaT Pharma, Merck/MSD, Organobalance, Seres Therapeutics, Takeda Pharmaceutical, as well as speaker fees and/or consulting fees from Alb Fils Kliniken GmbH, Arderypharm, Astellas Pharma, Basilea, Bio-Mérieux, DaVolterra, Farmak International Holding GmbH, Ferring, Gilead Sciences, Immunic AG, MaaT Pharma, Merck/MSD, Pfizer, Roche, Organobalance, SocraTec R&D GmbH, Tillots Pharma. MvLT has received travel grants and honoraria from Celgene, Gilead, Chugai, Janssen, Novartis, Amgen, Takeda, BMS, Medac, Oncopeptides, Merck, CDDF, Pfizer, medac, thermofisher, AstraZeneca; is a consultant for Celgene, Gilead, Oncopeptides, MSD, 4DPharma, Janssen, Shionogi, and received research funding from BMBF, Deutsche Jose Carreras Leukämie-Stiftung, IZKF Jena, DFG, Novartis, Gilead, Deutsche Krebshilfe, Celgene, Oncopeptides, Deutsche Forschungsgemeinschaft. MW received grants or contracts from Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Deutsche Gesellschaft für Pneumologie, European Respiratory Society, Marie Curie Foundation, Else Kröner Fresenius Stiftung, Capnetz Stiftung, Bayer Health Care and Biotest; consulting fees from Insmed Germany, Pantherna, Pherecydes, Aptarion, Glaxo Smith Kline, Inflarx, Biotest and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astra Zeneca, Insmed Germany, Chiesi, Novartis, Actelion, Boehringer Ingelheim, Glaxo Smith Kline, Biotest and Bayer Health Care. All other authors report no competing interest.
: The study protocol and its amendments were reviewed and approved by the Charité Ethics Committee (EA2/066/20, EA2/226/21) as well as local ethics committees at each participating study center.